PHVS — Pharvaris N.V.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1830487 · Netherlands
Last close
$32.28
Market Cap
$2.27B
52W High
$43.25
52W Low
$23.15
ADV30
591,343
Next earnings
2026-11-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -50,082,251 -47,412,993 295,063,721 282,732,818 30,089,488
Jun 2026 0 — -50,788,287 -47,842,729 328,667,391 318,282,453 27,856,887
Mar 2026 0 — -44,272,001 -39,200,673 259,788,041 246,957,998 23,455,647
Dec 2025 0 — -47,599,025 -46,740,853 301,454,999 291,678,888 30,180,665

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-155,188,603
Investing CF
$-99,256
Financing CF
$266,518,068
CapEx
$-99,256
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.73
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-668,576,894
Inventory
—
Receivables
$5,270,003
ST Investments
—
EBIT TTM
$-182,323,812
Pretax Income TTM
$-168,563,531
Interest Exp TTM
—
Analysts
14

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -169,822,932 -175,699,397 301,454,999 30,180,665 271,274,334 -137,073,634
Dec 2024 0 -145,688,167 -134,221,527 291,374,765 23,614,024 267,760,741 -120,130,191
Dec 2023 0 -96,913,620 -100,875,068 398,694,465 14,646,062 384,048,403 -93,049,093
Dec 2022 0 -86,714,608 -76,332,557 167,732,983 18,473,953 149,259,030 -67,162,634

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.15

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $30.00 · spot: $31.55 · call volume: 68 · put volume: 66

Peers — same industry

TickerNameMarket CapLastDaily %
LKFT Lakefront Biotherapeutics NV $2.25B $34.39 —
PBH Prestige Consumer Healthcare Inc. $2.29B $48.22 —
GLPGF Lakefront Biotherapeutics NV $2.30B $35.15 —
GRFS Grifols SA $2.23B $8.63 —
NAMS NewAmsterdam Pharma Co N.V. $2.33B $19.39 —

News headlines (Yahoo Finance, 1h cache)

Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?
2026-11-16 13:55 · Yahoo
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
2026-11-12 15:28 · Yahoo
Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 11:50 · Yahoo
Pharvaris (PHVS) Stock Could Look Pricey Following Phase 3 Momentum
2026-11-04 15:11 · Yahoo
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
2026-10-29 10:50 · Yahoo
Bank of America backs Pharvaris on breakthrough for rare swelling disease
2026-10-26 23:00 · Yahoo
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
2026-10-08 22:35 · Yahoo
Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?
2026-10-08 15:10 · Yahoo
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
2026-10-05 10:50 · Yahoo
What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?
2026-09-19 15:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.